NCT03122431View on ClinicalTrials.gov

Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

December 30, 2020

Study Completion Date

March 30, 2021

Conditions
Systemic Lupus Erythematosus (SLE)Juvenile SLECutaneous Lupus
Interventions
DRUG

Thalidomide

Thalidomide 100 mg/day

DRUG

Hydroxychloroquine reduced

Hydroxychloroquine 2.5 mg/kg/day

DRUG

standard dose of HCQ

Hydroxychloroquine 5.0 mg/kg/day

Trial Locations (1)

05403-000

Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Sao Paulo General Hospital

OTHER

NCT03122431 - Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases | Biotech Hunter | Biotech Hunter